Featured Publications

Fig8 Bristol Partnership

In partnership with Bristol-Myers Squibb, Immuneering helped BMS understand why only a certain group of patients with melanoma were responding to YERVOY. We detected gene expression in a subset of immune cells and were able to show that patients with that gene had an increased survival benefit. This work resulted in a new patent application (WO2014078468).

Learn More

BCMA - Janssen Partnership

In published work together with Janssen, Immuneering helped identify why subgroups of multiple myeloma (MM) patients treated with DARZALEX had different response profiles through discovering differential expression of T-cell co-stimulation proteins in better responding patients. This work resulted in several published abstracts and presentations at the American Society of Hematology.

Learn More

Copaxone Fig Teva Partnership

In partnership with Teva, Immuneering applied transcriptomics to characterize COPAXONE’s mechanism of action and compare it to potential generics, helping to ensure patient safety by providing new ways to more fully assess the biological impact of potential generics. This work resulted in several peer-reviewed publications.

Learn More

Publications

Found 61 Results
Page 1 of 7

Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing

The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….

Journal: Nature Biotechnology


Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study…

Journal: Nature Biotechnology


Human transthyretin binding affinity of halogenated thiophenols and halogenated phenols: An in vitro and in silico study

Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory…

Journal: Chemosphere


A primer on applying AI synergistically with domain expertise to oncology

Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model it has created a promising environment for revolutionizing cancer diagnosis, treatment,…

Journal: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer


A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having…

Journal: Genome Biology


Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence…

Journal: Genome Biology


Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…

Journal: Nature Biotechnology


Transparency and reproducibility in artificial intelligence

Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…

Journal: Nature


Clinical landscape of oncolytic virus research in 2020

Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…

Journal: Journal for ImmunoTherapy of Cancer


pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model

Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.

Journal: Cell Death & Disease


Page 1 of 7